GRI Bio (GRI) Competitors

Minerva Neurosciences (NASDAQ:NERV) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation, community ranking and media sentiment.

Does the media prefer NERV or GRI?

In the previous week, GRI Bio had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 2 mentions for GRI Bio and 1 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.00 beat GRI Bio's score of -0.17 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GRI Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community prefer NERV or GRI?

Minerva Neurosciences received 343 more outperform votes than GRI Bio when rated by MarketBeat users. However, 100.00% of users gave GRI Bio an outperform vote while only 55.52% of users gave Minerva Neurosciences an outperform vote.

Company	Underperform	Outperform
Minerva Neurosciences	Outperform Votes 347 55.52%	Underperform Votes 278 44.48%
GRI Bio	Outperform Votes 4 100.00%	Underperform Votes No Votes

Is NERV or GRI more profitable?

Minerva Neurosciences' return on equity of 0.00% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-6.74%
GRI Bio	N/A	-289.05%	-165.01%

Do insiders & institutionals believe in NERV or GRI?

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 34.0% of GRI Bio shares are held by institutional investors. 8.6% of Minerva Neurosciences shares are held by company insiders. Comparatively, 0.1% of GRI Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has higher earnings & valuation, NERV or GRI?

GRI Bio is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$30M	$0.82	1.84
GRI Bio	N/A	N/A	-$13.04M	-$11.56	-0.11

Which has more risk & volatility, NERV or GRI?

Minerva Neurosciences has a beta of -0.5, indicating that its stock price is 150% less volatile than the S&P 500. Comparatively, GRI Bio has a beta of -1.67, indicating that its stock price is 267% less volatile than the S&P 500.

Do analysts prefer NERV or GRI?

Minerva Neurosciences presently has a consensus target price of $5.00, suggesting a potential upside of 231.35%. GRI Bio has a consensus target price of $115.50, suggesting a potential upside of 9,140.74%. Given GRI Bio's stronger consensus rating and higher probable upside, analysts clearly believe GRI Bio is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
GRI Bio	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Minerva Neurosciences beats GRI Bio on 8 of the 15 factors compared between the two stocks.